Cao, Yanshuo
Lu, Ming
Sun, Yu
Gong, Jifang
Li, Jie
Lu, Zhihao
Li, Jian
Zhang, Xiaotian
Li, Yan
Peng, Zhi
Zhou, Jun
Wang, Xicheng
Shen, Lin http://orcid.org/0000-0003-1134-2922
Clinical trials referenced in this document:
Documents that mention this clinical trial
Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
https://doi.org/10.1007/s00432-021-03898-8
Funding for this research was provided by:
National Key Research and Development Program of China (2017YFC0908404)
Article History
Received: 6 November 2021
Accepted: 21 December 2021
First Online: 15 February 2022
Declarations
:
: The authors declare no potential conflicts of interest.
: This clinical trial was approved by Ethics Committee of Peking University Cancer Hospital and was conducted strictly in accordance with the Declaration of Helsinki and Good Clinical Practice.
: All patients provided written informed consent form (ICF) before enrollment.